Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH1902 in Advanced Solid Tumors
NCT04706962Phase 1Active, not recruiting
- Sponsor
- Theratechnologies Inc.
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sudocetaxel zendusortide in solid tumor, triple-negative breast cancer (TNBC), hormone receptor-positive breast cancer and 10 more, sponsored by Theratechnologies Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 12 weeks, Maximum Tolerated Dose at 21 days and 1 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
sudocetaxel zendusortide
03
Conditions
solid tumortriple-negative breast cancer (TNBC)hormone receptor-positive breast cancerepithelial ovarian cancer (EOC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04706962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706962.